Kastelein Johannes Jacob Pieter 4

What Happened
Johannes Jacob Pieter Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma (NAMS), sold 45,481 shares in two open‑market transactions on February 20, 2026. The sales consisted of 14,692 shares at a weighted average price of $35.00 (proceeds $514,220) and 30,789 shares at a weighted average price of $35.46 (proceeds $1,091,778), for total proceeds of $1,605,998. These were sales (not purchases), so they are not a bullish insider buy signal.

Key Details

• Transaction date: 2026-02-20 (reported on Form 4 filed 2026-02-24). Filing appears within the SEC’s two-business-day requirement for a Feb 20 trade.
• Prices and ranges: first block weighted avg $35.00 (individual trades ranged $34.24–$35.23) [F1]; second block weighted avg $35.46 (individual trades ranged $35.24–$35.86) [F2].
• Shares sold: 14,692 and 30,789 (total 45,481).
• Total proceeds: $1,605,998.
• Shares owned after transaction: not provided in the summary above; see the filed Form 4 for post-sale holdings.
• Footnotes: both price figures are weighted averages from multiple trades; the reporting person will provide a full breakdown of individual trade sizes/prices to the company, shareholders, or SEC staff upon request.

Context

• These were open‑market sales reported under code "S" (sale). Sales by executives can be routine (diversification, tax planning, etc.); the filing itself does not indicate the insider’s motivation.
• No option exercises, awards, gifts, or tax‑withholding transactions are indicated in this filing.